WASHINGTON, June 10 /PRNewswire/ -- New research presented today at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) show the benefits of the initial use of Avandaryl in helping people with type 2 diabetes achieve blood sugar targets and improving insulin sensitivity. These data suggest that treatment of drug-naive people with Avandaryl may be more efficacious than using one therapy alone. Avandaryl is the only therapy available that combines a thiazolidinedione (TZD), rosiglitazone maleate -- separately marketed as Avandia® -- with a sulfonylurea, glimepiride -- separately marketed as Amaryl® -- to treat type 2 diabetes.
